I also posted on an interesting analysis of generic drug costs in the supposedly free market that exists after patent expiration.
While technically from last week, I wrote a little legal analysis of the “Who Dat?” IP controversy, an announcement of David Ellerman’s new blog, a rant against single-payer, about the appearance of the broken window fallacy in the SOTU, and some career advice for Eddie Izzard.
]]>